首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL9 |
| Uniprot No | Q07325 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-125aa |
| 氨基酸序列 | TPVVRKGRCSCISTNQGTIHLQSLKDLKQFAPSPSCEKIEIIATLKNGVQ TCLNPDSADVKELIKKWEKQVSQKKKQKNGKKHQKKKVLKVRKSQRSRQK KTT |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL9重组蛋白的3篇代表性文献示例(内容为虚构示例，仅用于演示格式)：
1. **《Recombinant CXCL9 Protein Enhances T Cell Migration in Vitro》**
- 作者：Smith A, et al.
- 摘要：研究报道了通过大肠杆菌系统高效表达和纯化CXCL9重组蛋白的方法，并证明其在体外实验中显著促进CD8+ T细胞的趋化迁移，提示其潜在的免疫调节应用。
2. **《Structural and Functional Characterization of CXCL9 in Autoimmune Disease Models》**
- 作者：Li H, et al.
- 摘要：通过晶体学分析揭示了CXCL9重组蛋白的三维结构，并在类风湿性关节炎小鼠模型中验证了其通过结合CXCR3受体抑制炎症反应的机制。
3. **《CXCL9 Recombinant Protein Modulates Tumor Microenvironment in Melanoma》**
- 作者：Garcia R, et al.
- 摘要：研究利用哺乳动物细胞表达系统生产的CXCL9重组蛋白，发现其能招募抗肿瘤T细胞浸润黑色素瘤组织，显著增强PD-1抑制剂疗法的疗效。
*注：以上文献信息为模拟生成，实际引用需查询PubMed、Google Scholar等数据库获取真实研究。*
CXCL9. a member of the CXC chemokine family, is a small cytokine primarily secreted by interferon-gamma (IFN-γ)-activated macrophages, endothelial cells, and dendritic cells. It plays a critical role in immune responses by recruiting effector T cells and natural killer (NK) cells to sites of inflammation or tumorigenesis through interaction with its receptor CXCR3. CXCL9 is structurally characterized by conserved cysteine residues (C-X-C motif) and shares functional redundancy with CXCL10 and CXCL11. collectively forming the CXCR3 ligand group. These chemokines are pivotal in Th1-mediated immunity, autoimmune diseases, and cancer immunology.
Recombinant CXCL9 protein is engineered using prokaryotic (e.g., E. coli) or eukaryotic expression systems to ensure proper folding and post-translational modifications. Its production typically involves cloning the CXCL9 gene into expression vectors, followed by purification via affinity chromatography (e.g., His-tag) and endotoxin removal. The recombinant protein retains bioactivity in vitro, including chemotactic assays and receptor-binding studies, making it a vital tool for studying immune cell migration, inflammatory pathways, and tumor microenvironment regulation.
Research applications include investigating CXCL9's role in diseases like cancer (e.g., promoting anti-tumor immunity or resistance to checkpoint inhibitors), autoimmune disorders (e.g., rheumatoid arthritis), and infections. It is also explored as a therapeutic target or biomarker in clinical settings. Quality control assays (e.g., SDS-PAGE, ELISA, functional cell migration tests) confirm its purity, stability, and biological activity. As a research reagent, recombinant CXCL9 facilitates mechanistic studies and preclinical drug development, bridging molecular insights to potential therapeutic strategies.
×
